TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
1.080
0.00 (0.00%)
At close: May 29, 2026, 4:00 PM EDT
1.100
+0.020 (1.85%)
After-hours: May 29, 2026, 7:46 PM EDT
TScan Therapeutics Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, TScan Therapeutics stock has a consensus rating of "Buy" and an average price target of $6.00. The average 1-year stock price forecast is 455.56% higher than the current stock price, while the lowest is $5.00 (+362.96%) and the highest is $7.00 (+548.15%).
Price Target: $6.00 (+455.56%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for TScan Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 5 | 5 | 3 | 5 | 5 | 5 |
| Hold | 2 | 2 | 2 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 5 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Maintains $5 | Buy | Maintains | $5 | +362.96% | May 8, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Reiterates $6 | Buy | Reiterates | $6 | +455.56% | May 7, 2026 |
| Needham | Needham | Buy Maintains $6 | Buy | Maintains | $6 | +455.56% | May 6, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $7 | Buy | Reiterates | $7 | +548.15% | May 6, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Mar 12, 2026 |
Financial Forecast
Revenue This Year
7.47M
from 10.33M
Decreased by -27.62%
Revenue Next Year
10.33M
from 7.47M
Increased by 38.23%
EPS This Year
-0.89
from -1.00
EPS Next Year
-0.99
from -0.89
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 11.4M | 12.0M | ||||||
| Avg | 7.5M | 10.3M | ||||||
| Low | 962,360 | 8.8M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 10.2% | 59.9% | ||||||
| Avg | -27.6% | 38.2% | ||||||
| Low | -90.7% | 18.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.88 | -0.91 | ||||||
| Avg | -0.89 | -0.99 | ||||||
| Low | -0.89 | -1.12 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.